Bayer’s Finerenone Shows Renal, CV Benefits In CKD/Type 2 Diabetes Patients – But Is It Enough?
Executive Summary
Study shows risk reduction in both renal failure and cardiovascular events, but analysts question competitiveness versus SGLT-2 inhibitors and safety compared to earlier MR antagonists.
You may also be interested in...
Bayer's Finerenone Stacks Up More CV Benefit Data Ahead Of Potential Approval
The FIGARO-DKD cardiovascular outcomes trial showed finerenone reduced composite risk of CV death or non-fatal events in CKD patients with Type 2 diabetes, including earlier-stage patients.
Bayer Confident CureVac COVID Pact Will Be A Success
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
What Pandemic Effect? US FDA’s 2021 Approval Class Is Off To Strong Start With 60+ Novel Candidates
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.